This article is more than 5 years old. Information may no longer be current.

Once-daily timolol liquid launched in United States

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Istalol, a once-daily formulation of timolol, has been launched in the U.S. market, according to marketer Ista Pharmaceuticals. The formulation received U.S. regulatory approval in June.

Ista said in a press release that the first shipments to wholesalers and warehousing chains will occur within the next week. Istalol is a topical beta-blocker for the treatment of glaucoma. Ista holds exclusive marketing rights to the drug as part of a licensing deal with Japanese pharmaceutical company Senju Pharmaceutical. Animal studies showed the drug to have enhanced corneal penetration when compared to other formulations, according to Ista.